MacroGenics (MGNX)
(Delayed Data from NSDQ)
$1.61 USD
-0.08 (-4.73%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.62 +0.01 (0.62%) 7:54 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MGNX 1.61 -0.08(-4.73%)
Will MGNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MGNX
SNDL Inc. (SNDL) Surpasses Q2 Earnings and Revenue Estimates
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
MGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
4 Medical Product Stocks to Watch From a Challenging Industry
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
Other News for MGNX
MacroGenics Advances Cancer Treatment with MGC026 Study Update
MacroGenics (MGNX) Receives a Hold from Stifel Nicolaus
MacroGenics (MGNX) Gets a Hold from Citizens JMP
MacroGenics: Working On That Road To Recovery
MacroGenics (MGNX) Secures $70M Upfront Payment in Royalty Deal